PL2958550T3 - Doustna postać użytkowa i zawiesina leku onkologicznego - Google Patents

Doustna postać użytkowa i zawiesina leku onkologicznego

Info

Publication number
PL2958550T3
PL2958550T3 PL14710642.1T PL14710642T PL2958550T3 PL 2958550 T3 PL2958550 T3 PL 2958550T3 PL 14710642 T PL14710642 T PL 14710642T PL 2958550 T3 PL2958550 T3 PL 2958550T3
Authority
PL
Poland
Prior art keywords
suspension
oral formulation
oncology drug
oncology
drug
Prior art date
Application number
PL14710642.1T
Other languages
English (en)
Inventor
Céline DECAUDIN
Vincent ROGUE
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of PL2958550T3 publication Critical patent/PL2958550T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL14710642.1T 2013-02-25 2014-02-21 Doustna postać użytkowa i zawiesina leku onkologicznego PL2958550T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361768803P 2013-02-25 2013-02-25
PCT/IB2014/059161 WO2014128661A1 (en) 2013-02-25 2014-02-21 Oral formulation and suspension of an oncology drug

Publications (1)

Publication Number Publication Date
PL2958550T3 true PL2958550T3 (pl) 2023-01-16

Family

ID=50288200

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14710642.1T PL2958550T3 (pl) 2013-02-25 2014-02-21 Doustna postać użytkowa i zawiesina leku onkologicznego

Country Status (11)

Country Link
US (2) US9943520B2 (pl)
EP (1) EP2958550B1 (pl)
JP (1) JP6310484B2 (pl)
AR (1) AR094879A1 (pl)
AU (1) AU2014220339B2 (pl)
ES (1) ES2935528T3 (pl)
IL (2) IL240629B (pl)
PL (1) PL2958550T3 (pl)
TW (2) TWI684462B (pl)
WO (1) WO2014128661A1 (pl)
ZA (1) ZA201506012B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016155630A1 (zh) * 2015-03-30 2016-10-06 苏州晶云药物科技有限公司 N-[6-(顺式-2,6-二甲基吗啉-4-基)吡啶-3-基]-2-甲基-4'-(三氟甲氧基)[1,1'-联苯]-3-甲酰胺单磷酸盐的晶型及其制备方法
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof
CN116327772B (zh) * 2021-12-22 2025-05-16 中国科学院上海营养与健康研究所 SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
JO2889B1 (en) * 2008-09-17 2015-03-15 نوفارتيس ايه جي Salts 6N - (CIS-2, 6-dimethyl morpholine-4-yl) pyridine-3-yl-methyl-4 ’- (tetrafluoromethoxy) [1,1,-2-phenyl] -3-carboxamide
AR077490A1 (es) * 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
US8927718B2 (en) * 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
JP2012094104A (ja) * 2010-09-29 2012-05-17 Omron Corp 情報処理装置および方法、並びにプログラム

Also Published As

Publication number Publication date
TW201442738A (zh) 2014-11-16
EP2958550B1 (en) 2022-08-17
IL276838B (en) 2021-05-31
ES2935528T3 (es) 2023-03-07
JP6310484B2 (ja) 2018-04-11
US20160008369A1 (en) 2016-01-14
WO2014128661A1 (en) 2014-08-28
JP2016510724A (ja) 2016-04-11
US9943520B2 (en) 2018-04-17
IL240629B (en) 2020-09-30
AU2014220339B2 (en) 2016-12-01
US20180071305A1 (en) 2018-03-15
ZA201506012B (en) 2020-01-29
EP2958550A1 (en) 2015-12-30
TWI684462B (zh) 2020-02-11
AU2014220339A1 (en) 2015-09-17
US10426781B2 (en) 2019-10-01
TWI696470B (zh) 2020-06-21
TW202019392A (zh) 2020-06-01
IL276838A (en) 2020-10-29
AR094879A1 (es) 2015-09-02
IL240629A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
EP2981611A4 (en) ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
IL240290A0 (en) History of pyridazinone-amide and pharmaceutical preparations containing them
ZA201505735B (en) Cancer drug and uses
SG10201912735TA (en) Pharmaceutical composition of s-ketamine hydrochloride
EP3075736A4 (en) Mercaptoalkyl glycolurils and use of same
SG10201802104QA (en) Pharmaceutical composition of s-ketamine hydrochloride
IL240592A0 (en) Coated medical devices and methods for their preparation and use
IL245855B (en) Oral formulations of pyrrolidine derivatives
EP3038465A4 (en) Oral pharmaceutical formulation of omarigliptin
SG11201507643PA (en) Moldable capsule and method of manufacture
EP3068416A4 (en) Kava derived therapeutic compounds and methods of use thereof
IL244446A0 (en) History of deoxynogirimycin and methods of using them
IL240292A0 (en) History of quinazoline and pharmaceutical preparations containing them
IL276838B (en) Oral formulation and suspension of an oncology drug
HUE046485T2 (hu) Gyûrûs amin-származék és gyógyszerészeti alkalmazása
PL3598971T3 (pl) Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny
GB201518061D0 (en) Method of determining degree of modified potency of bipathic medicament
HUE041336T2 (hu) Petoxamid és pikloram kombinációja
IL243390A0 (en) Pharmaceutical preparations of ranolazine and dronedarone
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
PT3308791T (pt) Derivados carboxilados de glicosaminoglicanos e utilização como fármacos
GB201319437D0 (en) Delivery of drugs
EP3052475A4 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile
HK1225288A1 (en) Pharmaceutical compositions of ranolazine and dronedarone
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same